EQL Pharma Posts Record Quarter as European Expansion and Pipeline Drive Growth

EQL Pharma AB ( (SE:EQL) ) has provided an announcement.

EQL Pharma reported a record third quarter for 2025/26, with net sales rising 29% year-on-year to SEK 118.9 million and EBITDA up 44%, while gross and operating margins improved to 42% and 21% respectively despite lingering stock-outs on several key products. The company strengthened its balance sheet with cash of SEK 72.7 million and increased unused credit facilities, maintained its full-year sales growth forecast of around 15%, and continued to build its product base with one new launch, six additions to a 50-strong pipeline, and 47 marketed products. Management is pushing ahead with European expansion through regulatory filings and launch plans for key products Memprex and Mellozzan in BeNeLux, Germany, France, Italy and the GCC, while also addressing supply-chain resilience via improved supplier follow-up, inventory planning and an ERP feasibility study, aiming over time to lift profitability toward its long-term 25% EBITDA-margin target.

More about EQL Pharma AB

EQL Pharma AB is a specialty pharmaceutical company focused on developing and marketing niche generic and special generic medicines, primarily in the Nordic region and increasingly in broader European markets such as Germany, the Netherlands, BeNeLux, France and Italy. The company maintains a growing portfolio of launched products alongside an expanding pipeline, and is investing in international commercial capabilities and operational systems to support its geographic expansion and product roll-out strategy.

Average Trading Volume: 32,311

Technical Sentiment Signal: Hold

Current Market Cap: SEK1.78B

See more insights into EQL stock on TipRanks’ Stock Analysis page.